MacroGenics, Inc. (MGNX) Income Statement

The quarterly pattern points to collaboration or licensing recognition events rather than a steady product revenue stream, which makes year-over-year growth rates such as 154.4% in 2026Q2 difficult to read as trend signals. Investors should monitor whether the revenue base can be sustained between milestone recognitions, since the reported figures do not show a consistent compounding trajectory. The lack of a stable floor warrants further investigation into the contractual timing of future receipts.

The sharp swing from 81.6% to negative gross margin in consecutive reporting periods reflects cost of revenue that does not scale with revenue, so gross profit is primarily a function of when licensing revenue is recognized. This pattern suggests limited structural pricing power and makes the gross margin a poor indicator of underlying unit economics. Analysts should treat historical gross margin averages with caution given the event-driven nature of the top line.

Because R&D spending stayed elevated in quarters with strong revenue, incremental revenue did not translate into proportional operating income gains, which is typical of a clinical-stage cost base carrying fixed development spend. The positive operating result in 2024Q3 and 2025Q3 appears to depend on single revenue events rather than a scalable cost curve. This suggests operating leverage remains unproven and warrants further investigation into the timing of development expenses.